Randomized trial · people

Exenatide ER: 0.9% HbA1c drop vs 1.5% with semaglutide in SUSTAIN 3

Checked against the paper Randomized trialPublished by PepVault

The takeaway

Head to head over 56 weeks, exenatide ER 2.0 mg lowered HbA1c and weight less than semaglutide 1.0 mg, with fewer gut side effects but more injection-site reactions.

Kind
Randomized trial
Studied in
People
Number studied
813
Published
2018
Journal
Diabetes Care

What they tested

The team tested whether once-weekly semaglutide 1.0 mg lowers blood sugar as well as or better than exenatide extended release (ER) 2.0 mg in people with type 2 diabetes.

How the study was done

A randomized, open-label, phase 3a trial (everyone knew which drug they got) in 813 adults with type 2 diabetes already on diabetes pills, split evenly between semaglutide 1.0 mg and exenatide ER 2.0 mg for 56 weeks. The main measure was the change in HbA1c, a 3-month average of blood sugar.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking exenatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

From a starting HbA1c of 8.3%, the exenatide ER arm dropped 0.9% and the semaglutide arm dropped 1.5%, an estimated gap of -0.62% in favor of semaglutide. Body weight, 95.8 kg at the start, fell 1.9 kg with exenatide ER and 5.6 kg with semaglutide. An HbA1c under 7.0% was reached by 40% on exenatide ER and 67% on semaglutide. Stomach and gut side effects hit 33.3% on exenatide ER and 41.8% on semaglutide, but reactions where the shot went in showed up in 22.0% of the exenatide ER arm, against 1.2% of the semaglutide arm.

What it doesn’t show

The trial was open-label and tested a single dose of each drug, only in people whose diabetes was not controlled on pills. It ran for 56 weeks, so it does not show longer-term results.

The paper

Ahmann et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018.

The compounds

More studies on Exenatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking exenatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo